Health economist cautions against new breast cancer drugBMJ 2005; 331 doi: http://dx.doi.org/10.1136/bmj.331.7528.1287-a (Published 01 December 2005) Cite this as: BMJ 2005;331:1287
- Lynn Eaton
Healthcare organisations should not rush into using trastuzumab (Herceptin) for early breast cancer without first examining the implications on budgets of doing so, warns a Belgian health economist.
Mattias Neyt of Ghent University had carried out an economic analysis of the benefits of the new breast cancer treatment. He also says that doctors should wait until the final results of clinical trials are published so that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial